Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).

Philippe Rochigneux,Anne-Sophie Chrétien,Delphine Rossille,Brice Chanez,Emilien Billon,Stephane Fattori,Romain Corre,Jihane Pakradouni,Anthony Gonçalves,Thierry Fest,Anne Madroszyk,Daniel Olive

Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).

2020

Philippe Rochigneux
Anne-Sophie Chrétien
Delphine Rossille
Brice Chanez
Emilien Billon
Stephane Fattori
Romain Corre
Jihane Pakradouni
Anthony Gonçalves
Thierry Fest
Anne Madroszyk
Daniel Olive

9561Background: Medical treatment of lung cancer has irreversibly changed since the development of immune checkpoint inhibitors (ICI). However, immune biomarkers of efficacy are still lacking. Prel...

Keywords:

predictive biomarker
Pathology
immune checkpoint inhibitors
non-small cell lung cancer (NSCLC)
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations